Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.

Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.

Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.

Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.